Glenmark’s monoclonal antibody ‘GBR 830’ enters human trials

04 Jul 2014 Evaluate

Glenmark Pharmaceuticals’ wholly owned Swiss subsidiary - Glenmark Pharmaceuticals S.A., new molecule - GBR 830, a novel monoclonal antibody is entering human trials. GBR 830 is a pure antagonist of OX40, a co-stimulatory receptor expressed on T cells mediating T cell activation and survival.

The company has now completed the Phase I enabling preclinical development program for GBR 830 and has filed a Phase I clinical trial application with The Netherlands authorities. GBR 830 is the first OX40 antagonistic antibody devoid of agonistic properties to enter clinical studies.

OX40 is a very well validated target with the potential to treat a wide array of autoimmune diseases. However, discovering antibodies that inhibit OX40 and do not have agonistic properties, which would lead to unwanted side effects, has proven very difficult and based on Glenmark’s data GBR 830 is devoid of any agonistic properties.

Glenmark Pharma Share Price

2022.95 -12.95 (-0.64%)
01-Jan-2026 09:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1712.00
Dr. Reddys Lab 1253.30
Cipla 1501.30
Zydus Lifesciences 909.00
Lupin 2092.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×